Non-alcoholic fatty liver disease, diabetes medications and blood pressure

doi:10.4239/wjd.v12.i10.1809

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4402)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

272

WORD

130

HTML

2099

Sum=2501

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

506

Download

1401

Sum=1907

Oct 15, 2021 (publication date) through Feb 26, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Letter to the Editor

World J Diabetes. Oct 15, 2021; 12(10): 1809-1811
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1809

Non-alcoholic fatty liver disease, diabetes medications and blood pressure

Ioannis Ilias, Costas Thomopoulos

Ioannis Ilias, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, Athens 11521, Greece

Costas Thomopoulos, Department of Cardiology, Elena Venizelou Hospital, Athens 11521, Greece

Author contributions: Both Ilias I and Thomopoulos C conceived this work, performed the literature research, wrote this letter and revised it.

Conflict-of-interest statement: The authors declare no conflict of interest.

Corresponding author: Ioannis Ilias, MD, PhD, Consultant Physician-Scientist, Department of Endocrinology, Diabetes and Metabolism, Elena Venizelou Hospital, 2, El Venizelou Square, Athens 11521, Greece. iiliasmd@yahoo.com

Received: May 23, 2021
Peer-review started: May 23, 2021
First decision: June 16, 2021
Revised: June 22, 2021
Accepted: September 6, 2021
Article in press: September 6, 2021
Published online: October 15, 2021
Processing time: 142 Days and 23 Hours

Abstract

New glucose-lowering agents reduce liver enzyme levels and blood pressure (BP). Whether this finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown.

Keywords: Antidiabetic drugs; Blood pressure reduction; Non-alcoholic fatty liver disease; Sodium glucose cotransporter 2; Alanine aminotransferase; Aspartate aminotransferase

Core Tip: All new glucose-lowering agents reduce liver enzyme levels. Additionally, sodium glucose cotransporter 2 inhibitors can reduce both systolic and diastolic blood pressure (BP) by 3.5/1 mmHg, respectively, while glucagon-like peptide-1 agonist treatment was accompanied by systolic BP reduction of 1 mmHg. Whether this previous finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown.